U.S., Sept. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07800520) titled 'Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder' on Aug. 28.
Brief Summary: The goals of this sub-study is to assess CB1R availability in early abstinent individuals with OUD (following opioid agonist therapy - OAT stabilization) and in matched healthy controls.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Opioid Use Disorder
OAT
Intervention:
DRUG: [11C]OMAR
For each [11C]OMAR PET scan, up to 20 mCi of [11C]OMAR will be administered.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Yale University
Information provided by (Responsible Party): Anahita Bassir Nia, Yale Universi...